A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI.
Koul, Sasha LU ; Andell, Pontus LU ; Martinsson, Andreas LU ; Smith, Gustav LU ; Scherstén, Fredrik LU ; Harnek, Jan LU ; Götberg, Matthias LU ; Norström, Eva LU ; Björnsson, Sven LU and Erlinge, David LU
(2014)
In BMC Cardiovascular Disorders
14.
- Abstract
- Despite advances in anti-platelet treatments, there still exists an early increase in both ischemic as well as bleeding events following primary PCI in patients with ST-elevation myocardial infarction (STEMI). Platelet inhibition data of different anti-platelet treatments in the acute phase of a myocardial infarction might offer some insight into these problems. The aim of this study was to evaluate the pharmacodynamic profile of 5 different anti-platelet treatments in the acute phase of STEMI in patients undergoing primary PCI.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4908115
- author
- Koul, Sasha
LU
; Andell, Pontus
LU
; Martinsson, Andreas
LU
; Smith, Gustav
LU
; Scherstén, Fredrik
LU
; Harnek, Jan
LU
; Götberg, Matthias
LU
; Norström, Eva
LU
; Björnsson, Sven
LU
and Erlinge, David
LU
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- in
- BMC Cardiovascular Disorders
- volume
- 14
- article number
- 189
- publisher
- BioMed Central (BMC)
- external identifiers
-
- pmid:25516485
- wos:000347348900001
- scopus:84988457258
- ISSN
- 1471-2261
- DOI
- 10.1186/1471-2261-14-189
- language
- English
- LU publication?
- yes
- id
- 8405cc74-802b-4cfa-a921-6ee2b7ff3f33 (old id 4908115)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25516485?dopt=Abstract
- date added to LUP
- 2016-04-01 13:05:29
- date last changed
- 2022-04-29 18:12:49
@article{8405cc74-802b-4cfa-a921-6ee2b7ff3f33,
abstract = {{Despite advances in anti-platelet treatments, there still exists an early increase in both ischemic as well as bleeding events following primary PCI in patients with ST-elevation myocardial infarction (STEMI). Platelet inhibition data of different anti-platelet treatments in the acute phase of a myocardial infarction might offer some insight into these problems. The aim of this study was to evaluate the pharmacodynamic profile of 5 different anti-platelet treatments in the acute phase of STEMI in patients undergoing primary PCI.}},
author = {{Koul, Sasha and Andell, Pontus and Martinsson, Andreas and Smith, Gustav and Scherstén, Fredrik and Harnek, Jan and Götberg, Matthias and Norström, Eva and Björnsson, Sven and Erlinge, David}},
issn = {{1471-2261}},
language = {{eng}},
publisher = {{BioMed Central (BMC)}},
series = {{BMC Cardiovascular Disorders}},
title = {{A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI.}},
url = {{https://lup.lub.lu.se/search/files/3153857/7751676}},
doi = {{10.1186/1471-2261-14-189}},
volume = {{14}},
year = {{2014}},
}